会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 21. 发明授权
    • Sustained-release preparation
    • 缓释制剂
    • US5480868A
    • 1996-01-02
    • US162698
    • 1993-12-07
    • Shigeru KameiYasutaka IgariYasuaki Ogawa
    • Shigeru KameiYasutaka IgariYasuaki Ogawa
    • A61K9/52A61K20060101A61K9/16A61K9/22A61K9/50A61K38/04A61K38/09A61K38/12A61K47/34A61K47/42C07K7/23A61K38/00C08G63/08C08G63/91C08L67/00
    • C07K7/23A61K38/09A61K9/1647A61K38/00
    • A sustained-release preparation which comprises a physiologically active peptide of general formula ##STR1## wherein X represents an acyl group; R.sub.1, R.sub.2 and R.sub.4 each represents an aromatic cyclic group; R.sub.3 represents a D-amino acid residue or a group of the formula ##STR2## wherein R.sub.3 ' is a heterocyclic group; R.sub.5 represents a group of the formula --(CH.sub.2).sub.n --R.sub.5 ' wherein n is 2 or 3, and R.sub.5 ' is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group;R.sub.6 represents a group of the formula --(CH.sub.2).sub.n --R.sub.6 ' wherein n is 2 or 3, and R.sub.6 ' is an amino group which may optionally be substituted;R.sub.7 represents a D-amino acid residue or an azaglycyl residue; andQ represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group.The sustained-release preparation shows a constant release of the peptide over a long time and is substantially free from an initial burst.
    • 包含通式的生理活性肽的缓释制剂含有酰基; R1,R2和R4各自表示芳族环状基团; R3表示D-氨基酸残基或式“IMAGE”的基团,其中R3'为杂环基; R5表示式 - (CH2)n-R5'的基团,其中n为2或3,R5'为任选取代的氨基,芳族环基或O-糖基; R6表示式 - (CH2)n-R6'的基团,其中n为2或3,R6'为可任意取代的氨基; R7表示D-氨基酸残基或氮杂十八烷基残基; Q表示氢或低级烷基,或其盐和具有末端羧基的生物降解性聚合物。 持续释放制剂显示长时间的肽的恒定释放并且基本上没有初始爆发。
    • 26. 发明授权
    • Code reading apparatus and computer program product
    • 代码阅读器和计算机程序产品
    • US08608075B2
    • 2013-12-17
    • US13435724
    • 2012-03-30
    • Masanori TanimotoYasuaki OgawaKeiichi Tanioka
    • Masanori TanimotoYasuaki OgawaKeiichi Tanioka
    • G06K7/10
    • G06K7/10811G06K7/10722
    • Disclosed is a code reading apparatus including a control section including: a first adjustment section repeating focus setting within a first execution time to execute first focus adjustment; a second adjustment section changing a focal position of a variable focal lens within a second execution time to execute second focus adjustment; a timer section counting a first execution number of the first focus adjustment and a second execution number of the second focus adjustment; and a time setting section setting the first execution time to be shortened starting from a predetermined first initial set time such that the first execution time is shortened as the first execution number increases, and setting the second execution time to be shortened starting from a predetermined second initial set time such that the second execution time is shortened as the second execution number increases.
    • 公开了一种代码读取装置,包括:控制部分,包括:第一调整部分,在第一执行时间内重复聚焦设置,以执行第一焦点调整; 第二调整部分,在第二执行时间内改变可变焦点透镜的焦点位置,以执行第二焦点调整; 计数第一焦点调整的第一执行次数和第二焦点调整的第二执行次数的定时器部分; 以及时间设定部,其从预定的第一初始设定时刻开始,将第一执行时间设定为缩短,使得随着第一执行次数增加,第一执行时间缩短,并且从预定秒开始将第二执行时间设定为缩短 初始设定时间,使得随着第二执行次数增加,第二执行时间缩短。
    • 29. 发明授权
    • Sustained-release preparation
    • 缓释制剂
    • US5668111A
    • 1997-09-16
    • US471382
    • 1995-06-06
    • Shigeru KameiYasutaka IgariYasuaki Ogawa
    • Shigeru KameiYasutaka IgariYasuaki Ogawa
    • A61K9/52A61K20060101A61K9/16A61K9/22A61K9/50A61K38/04A61K38/09A61K38/12A61K47/34A61K47/42C07K7/23A61K38/00C08G63/08
    • C07K7/23A61K38/09A61K9/1647A61K38/00
    • A sustained-release preparation which comprises a physiologically active peptide of general formula ##STR1## wherein X represents an acyl group; R.sub.1, R.sub.2 and R.sub.4 each represents an aromatic cyclic group; R.sub.3 represents a D-amino acid residue or a group of the formula ##STR2## wherein R.sub.3 ' is a heterocyclic group; R.sub.5 represents a group of the formula --(CH.sub.2).sub.n --R.sub.5 ' wherein n is 2 or 3, and R.sub.5 ' is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group;R.sub.6 represents a group of the formula --(CH.sub.2).sub.n --R.sub.6 ' wherein n is 2 or 3, and R.sub.6 ' is an amino group which may optionally be substituted;R.sub.7 represents a D-amino acid residue or an azaglycyl residue; andQ represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group.The sustained-release preparation shows a constant release of the peptide over a long time and is substantially free from an initial burst.
    • 包含通式的生理活性肽的缓释制剂含有酰基; R1,R2和R4各自表示芳族环状基团; R 3表示D-氨基酸残基或式(D)的基团,其中R 3'为杂环基; R5表示式 - (CH2)n-R5'的基团,其中n为2或3,R5'为任选取代的氨基,芳族环基或O-糖基; R6表示式 - (CH2)n-R6'的基团,其中n为2或3,R6'为可任意取代的氨基; R7表示D-氨基酸残基或氮杂十八烷基残基; Q表示氢或低级烷基,或其盐和具有末端羧基的生物降解性聚合物。 持续释放制剂显示长时间的肽的恒定释放并且基本上没有初始爆发。